Last reviewed · How we verify
Lu-177 DOTA-TATE
Lu-177 DOTA-TATE is a radiolabeled peptide that targets somatostatin receptors on neuroendocrine tumors.
Lu-177 DOTA-TATE is a radiolabeled peptide that targets somatostatin receptors on neuroendocrine tumors. Used for Neuroendocrine tumors, including gastroenteropancreatic neuroendocrine tumors and somatostatin receptor-positive carcinoid tumors.
At a glance
| Generic name | Lu-177 DOTA-TATE |
|---|---|
| Sponsor | AHS Cancer Control Alberta |
| Drug class | Somatostatin receptor-targeting peptide |
| Target | Somatostatin receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by selectively binding to somatostatin receptors on the surface of tumor cells, allowing the radioactive payload to be delivered directly to the tumor site, where it can cause cell death through radiation damage.
Approved indications
- Neuroendocrine tumors, including gastroenteropancreatic neuroendocrine tumors and somatostatin receptor-positive carcinoid tumors
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Hypotension
Key clinical trials
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors (PHASE2)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu-177 DOTA-TATE CI brief — competitive landscape report
- Lu-177 DOTA-TATE updates RSS · CI watch RSS
- AHS Cancer Control Alberta portfolio CI